Abeona Therapeutics(US:ABEO)2025-11-12 12:30Financial Position - As of September 30, 2025, Abeona Therapeutics reported $207.5 million in cash, cash equivalents, restricted cash, and short-term investments, sufficient to fund operations for over two years[5] - Total assets increased to $231,095 million as of September 30, 2025, up from $108,931 million on December 31, 2024, representing a growth of 112%[17] - Cash and cash equivalents rose significantly to $82,884 million, compared to $23,357 million, marking an increase of 255%[17] - Total stockholders' equity increased to $171,233 million from $44,031 million, reflecting a growth of 288%[17] - Current liabilities increased to $22,180 million from $16,587 million, which is a rise of 34%[17] - The number of common shares outstanding increased to 52,400,415 as of September 30, 2025, up from 45,644,091 shares[17] - The accumulated deficit improved to $(721,615) million from $(813,258) million, indicating a reduction in losses[17] - Long-term debt decreased to $10,862 million from $13,037 million, showing a decline of 17%[17] - Total current assets reached $216,130 million, a significant increase from $100,853 million, representing a growth of 114%[17] - The company reported an increase in additional paid-in capital to $892,314 million from $856,824 million, reflecting a growth of 4%[17] - Warrant liabilities decreased to $22,566 million from $32,014 million, indicating a reduction of 29%[17] Revenue and Expenses - Research and development (R&D) spending for Q3 2025 was $4.2 million, a decrease of 53% from $8.9 million in Q3 2024, primarily due to costs capitalized into inventory[6] - Selling, general, and administrative (SG&A) expenses increased to $19.3 million in Q3 2025, compared to $6.4 million in Q3 2024, reflecting increased headcount and costs associated with the ZEVASKYN launch[6] - The net loss for Q3 2025 was $(5.2) million, or $(0.10) per share, significantly improved from a net loss of $(30.3) million, or $(0.63) per share, in Q3 2024[7] - The company reported a total revenue of $400,000 for the nine months ended September 30, 2025, with no revenue reported for the same period in 2024[15] Product Development and Market Acceptance - ZEVASKYN demand has more than doubled at Qualified Treatment Centers (QTCs), with approximately 30 eligible patients identified, and 12 product order forms received[2] - Coverage decisions for ZEVASKYN have been made by major commercial health plans covering approximately 80% of lives, indicating broad market acceptance[3] - The first anticipated ZEVASKYN patient treatment has been shifted to Q4 2025 due to a temporary pause in patient biopsy collection for assay optimization[1] - The company has activated three Qualified Treatment Centers (QTCs) for ZEVASKYN, with additional centers in various stages of onboarding[2] - The pipeline program ABO-503 has been selected for the FDA Rare Disease Endpoint Advancement Pilot Program, enhancing communication with the FDA[9]